IDEAYA Biosciences, Inc.
$3.29B- Market cap
- $3.85B
- Debt
- +$84.13M
- Cash
- −$639.39M
Capital structure 98% equity / 2% debt · EV / Revenue 15.06x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: IDYA stock price at premium vs AZO $39.88 current versus $5.83 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AZO's multiple
Implied fair value · at IDYA's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: IDYA FY 2025 (ended Dec 31, 2025) · AZO FY 2025 (ended Aug 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 15.06x
Capital structure 85% equity / 15% debt · EV / Revenue 3.02x · EV / EBITDA 16.13x
AZO carries the larger enterprise value at $57.23B against $3.29B; AZO trades on the lower EV / Revenue multiple (3.02x vs 15.06x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
IDEAYA Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
AUTOZONE INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.08x
-2.58x
Net debt / EBITDA
Leverage against operating earnings
4.97x
2.40x
Cash and equivalents
Liquid reserves on the balance sheet
$639.39M
$271.80M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zentalis Pharmaceuticals, Inc.
IDYA vs ZNTL
Blueprint Medicines Corp
IDYA vs BPMC
Jazz Pharmaceuticals plc
IDYA vs JAZZ
Sarepta Therapeutics, Inc.
IDYA vs SRPT
O REILLY AUTOMOTIVE INC
IDYA vs ORLY
ADVANCE AUTO PARTS INC
IDYA vs AAP
GENUINE PARTS CO
IDYA vs GPC
ETHAN ALLEN INTERIORS INC
IDYA vs ETD
NORDSTROM INC
IDYA vs JWN
ROSS STORES, INC.
IDYA vs ROST
$84.13M
$8.80B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.